IMPORTANT MESSAGE FROM ACT EU
All clinical trials expected to continue beyond 30 January 2025 must be transitioned to the EU Clinical Trials Regulation (CTR) via the Clinical Trials Information System (CTIS). This date marks the end of a three-year transition period that began when the CTR became...
🔔 📢 NEW PUBLICATION: Empowering Effective Biomarker-Driven Precision Oncology: A Call to Action (Lawler et al., 2024)
The Cancer Drug Development Forum (CDDF) is delighted to announce that a white paper, “Empowering Effective Biomarker-Driven Precision Oncology: A Call to Action” has been published in European Journal of Cancer (Vol 209, September 2024). This paper has been developed...
🔔 HMA/EMA Multi-stakeholder Workshop on Artificial Intelligence – 5 Nov 2024
Check out the hybrid joint HMA/EMA multi-stakeholder workshop on Artificial Intelligence (AI) that will be held on 5 November 2024. The objectives of the workshop is to provide an update on the state-of-the-art of AI developments with keynote speakers: Update...
ACT EU: Faster Access to Clinical Trial Information in Europe
The launch of a new version of the Clinical Trials Information System (CTIS) is giving earlier and more efficient access to clinical trial information in Europe. Revised transparency rules eliminate deferral mechanisms providing public access to approximately 4000...